Sort   by:  
 Page size 
ProteomicsKinome profiling in HER2+ breast cancer patients in response to 7 days of HER2-targeting
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site in...
ORGANISM(S): Homo sapiens (Human) 
2021-04-09 | PXD021865 | Pride
Pertuzumab Multiplexed kinase inhibitor beads Trastuzumab Erbb2 Clinical trial Lapatinib 
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Homo sapiens (Human) 
2024-11-20 | PXD036000 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Mus musculus (Mouse) 
2024-11-20 | PXD035998 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Mus musculus (Mouse) 
2024-11-20 | PXD035999 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
ProteomicsKinome profiling of Nf2-null murine Schwann cell line MS03 with defactinib and VS-4718
Patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN) develop hallmark tumors on their vestibular nerves, leading to hearing loss and numerous associated morbidities. Currently, there are no targeted therapeutic options for treating these tumors. In prior work, our group had ident...
ORGANISM(S): Mus musculus (Mouse) 
2025-09-17 | PXD060730 | Pride
Focal adhesion kinase inhibitor Neurofibromatosis type 2-related schwannomatosis Multiplexed kinase inhibitor beads Kinase inhibitor 
ProteomicsKinome profiling of WT and Nf2 KO human Schwann cell lines
Patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN) develop hallmark tumors on their vestibular nerves, leading to hearing loss and numerous associated morbidities. Currently, there are no targeted therapeutic options for treating these tumors. In prior work, our group had ident...
ORGANISM(S): Homo sapiens (Human) 
2025-09-19 | PXD068581 | Pride
Mib-ms Schwannoma Kinase 
UnknownBosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
Not available
S-EPMC10906575 | biostudies-literature
ProteomicsMicroscaled Proteogenomic Methods for Precision Oncology

Shankha Satpathy, Eric J. Jaehnig, et al., Nature Communications volume 11, Article number: 532 (2020)

Cancer proteogenomics promises new insights into cancer biology and treatment efficacy by integrating genom...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Mus Musculus (ncbitaxon:10090) 
2021-06-02 | MSV000087566 | MassIVE
ProteomicsProteogenomic Landscape Of Breast Cancer Tumorigenesis And Targeted Therapy
Karsten Krug, Eric J. Jaehnig, Shankha Satpathy, Lili Blumenberg, Alla Karpova, Meenakshi Anurag et al., (2020) Cell, 183, 1436-1456
DOI: https://doi.org/10.1016/j.cell.2020.10.036

The integration of ...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-06-05 | MSV000087576 | MassIVE
UnknownGrand Challenges at the Interface of Engineering and Medicine.
Not available
S-EPMC10896418 | biostudies-literature
Sort   by:  
 Page size